

1 Title

2 OLFACTORY TRAINING EFFICIENCY IN POST-COVID-19 PERSISTENT OLFACTORY DISORDERS

3

4 Running title

5 OLFACTORY TRAINING EFFICIENCY IN COVID-19 SMELL LOSS

6

7 Authors

8 Clair Vandersteen<sup>1,2</sup>, Magali Payne<sup>2,3</sup>, Louise-Émilie Dumas<sup>2,4</sup>, Élisabeth Cancian<sup>1</sup>, Alexandra

9 Plonka<sup>2,5,6</sup>, Grégoire D'Andrea<sup>1</sup>, David Chirio<sup>7</sup>, Élisabeth Demonchy<sup>7</sup>, Karine Risso<sup>7</sup>, Florence

10 Askenazy-Gittard<sup>2,4</sup>, Charles Savoldelli<sup>1</sup>, Nicolas Guevara<sup>1</sup>, Philippe Robert<sup>2,3,6</sup>, Laurent

11 Castillo<sup>1</sup>, Valeria Manera<sup>2,3</sup>, Auriane Gros<sup>2,3,6</sup>

12

13 Affiliation

14 <sup>1</sup>Institut Universitaire de la Face et du Cou, 31 Avenue de Valombrose, 06100, Centre Hospitalier Universitaire,  
15 Université Côte d'Azur, Nice, Alpes-Maritimes, France

16 <sup>2</sup>Université Côte d'Azur, laboratoire CoBTeK, Nice, France

17 <sup>3</sup>Université Côte d'Azur, Département d'Orthophonie de Nice, UFR Médecine, Nice, France.

18 <sup>4</sup>Hôpitaux Pédiatriques de Nice CHU-LENVAL, 57 Avenue de la Californie, 06200, Centre Hospitalier  
19 Universitaire, Université Côte d'Azur, Nice, Alpes-Maritimes, France

20 <sup>5</sup>Institut NeuroMod, INRIA Centre de recherche Sophia Antipolis, 2004 Route des Lucioles, 06902, Université  
21 Côte d'Azur, Sophia Antipolis, Alpes-Maritimes, France

22 <sup>6</sup>Centre Hospitalier Universitaire de Nice, Service Clinique Gériatrique du Cerveau et du Mouvement, Nice,  
23 France

24 <sup>7</sup>Département de médecine infectiologique, hôpital de l'archet, 151 route de Saint-Antoine, 06200, Centre  
25 Hospitalier Universitaire, Université Côte d'Azur, Nice, Alpes-Maritimes, France

26

27 **KEY WORDS:**

28 *COVID-19, OLFACTION DISORDERS, OLFACTORY TRAINING, PAROMIA*

29 **CORRESPONDING AUTHOR**

30

31 Dr. Clair Vandersteen, M.D

32 ENT surgery departement of Institut Universitaire de la Face et du Cou (IUFC)

33 31 Avenue de Valombrose

34 Centre Hospitalier Universitaire (CHU)

35 Université Côte D'Azur (UCA)

36 06100 – NICE – France

37

38 Tel : 04 92 03 17 61

39 Fax : 04 92 03 17 05

40 Mail : [vandersteen.c@chu-nice.fr](mailto:vandersteen.c@chu-nice.fr)

41 ORCID: 0000-0001-5597-2

42

43 **CONFLICT OF INTEREST**

44 None declared

45 **FUNDING**

46 None declared

47

48 **ABSTRACT**

49

50 **Background** - Persistent post-viral olfactory disorders (PPVOD) are widely reported after a  
51 COVID-19 and estimate to 30% one year after infection. Parosmias are the main qualitative  
52 dysosmia associated with olfaction recovery. No treatment is, to date, significantly efficient  
53 on PPVOD except olfactory training (OT). The main objective of this work was to evaluate OT  
54 efficiency on post-COVID-19 PPVOD.

55 **Methods** - Consecutive patients consulting to the ENT department with post-COVID-19  
56 PPVOD were included after mainly clinical examination, the complete Sniffin' Stick Test (TDI),  
57 the short version of the Questionnaire of olfactory disorders and the SF-36. Patients were  
58 trained to practice a self-olfactory training (professional manufactured olfactory training kit)  
59 twice a day for 6 months before coming back and undergo the same complete evaluation.

60 **Results** - Forty-three patients were included and performed 3,5 months of OT in average.  
61 There was a significant improvement in the mean TDI score increasing from 24,7 ( $\pm 8,9$ )  
62 before the OT to 30,9 ( $\pm 9,8$ ) ( $p < 0,001$ ). Parosmias increased significantly from 8 (18,6%) to  
63 27 (62.8%) ( $p < 0,001$ ). Based on normative data divided by sex and age, a significant increase  
64 in the number of normosmic participants was only found for the Threshold values ( $p < 0,001$ ).  
65 Specific and general olfaction-related quality of life improved after the OT.

66 **Conclusions** - OT seems to be efficient in post-COVID-19 PPVOD, probably on the peripheral  
67 regenerative part of the olfactory recovery. Future therapeutic strategies may focus on the  
68 central aspects of the post-COVID-19 PPVOD.

69

70

## 71 INTRODUCTION

72 Long persistent olfactory complaint is widely reported after an acute, mild, or  
73 moderate, COVID-19 infection. Indeed, a complete but subjective olfaction recovery is only  
74 reported in 40 to 63%<sup>(1-3)</sup> and 70%<sup>(4)</sup> of patients, respectively 6 and 12 months after COVID-  
75 19. Interestingly, olfactory psychophysical tests results are better than subjective smell  
76 assessments, showing 73% to 95% normosmic patients after 6 months<sup>(5,6)</sup>. Some authors  
77 suggested that these remaining olfactory complaining patients, with no recovery 18 months  
78 after acute phase<sup>(7)</sup>, could be permanently impaired. Parosmias are the main qualitative  
79 dysosmias associated with COVID-19 olfactory recovery and occurs in 18% to 49%<sup>(3,7,8)</sup> of  
80 patients 2,5 months after the acute phase of infection. Parosmias affects 20% of normosmic  
81 patients<sup>(3)</sup> and contributes to the discrepancy between subjective impairment and olfactory  
82 psychophysical tests.

83 Long lasting olfactory loss leads to a quality of life(QoL)<sup>(8)</sup> impairment, bad diet  
84 habits<sup>(9)</sup>, changes in social and personal relations<sup>(10)</sup>, psychiatric disorders (such as  
85 depression<sup>(11)</sup>), anxiety or anorexia<sup>(12)</sup> and its nutritional consequences<sup>(13)</sup>, cognitive  
86 impairment<sup>(10)</sup>, or increase of hazardous events incidence<sup>(14)</sup>. Thus they have to be managed.  
87 Many treatments<sup>(15)</sup> have been tried to get an olfaction recovery without significant results,  
88 including vitamins, minerals, corticosteroids, as well in COVID-19 as reported in a recent  
89 Cochrane living review<sup>(16)</sup>. Meanwhile, olfactory training (OT), as described by Pr. Thomas  
90 Hummel<sup>(17)</sup>, remains the best treatment for persistent post-viral olfactory disorder  
91 (PPVOD)<sup>(18)</sup>. Indeed, in PPVOD, OT systematically improve the Minimal Clinically Important  
92 Difference (MCID) of the complete Sniffin' Stick Test score (TDI; +6<sup>(17)</sup>) in 30 to 68% of cases  
93 (OR=2.77)<sup>(18)</sup>. However, the effectiveness of OT on COVID-19 patients with PPVOD is still  
94 unknown. The main objective of this work was to evaluate OT on PPVOD after a COVID-19.

95 MATERIAL AND METHODS

96

97 **Population**

98         The study was approved by the institutional review board of the Nice University  
99 Hospital (CNIL number: 412) and registered with a ClinicalTrials.gov number (ID:  
100 NCT04799977). Since March 2020, we prospectively enrolled patients at ENT division of Nice  
101 University Hospital until December 2020. All were contaminated by COVID-19 with  
102 persistent olfactory disorders lasting more than 6 weeks (3 to 15 months). Patients were  
103 mainly self-referred or referred by general practitioners or colleagues. Patients had either a  
104 RT-PCR-proven SARS-CoV-2 diagnosis or a CT-proven SARS-CoV-2 diagnosis secondarily  
105 confirmed by serology. We retrospectively extracted patients' demographic data and  
106 clinical features including subjective taste impairment, subjective olfactory impairment  
107 (qualitative and quantitative dysosmia), a visual analogue scale (VAS) for the subjective  
108 assessment of olfactory recovery (ranging from 0% to 100%), weight (measured at home in  
109 the previous week on a personal scale), a nasofibroscope (assessing nasal cavity patency and  
110 differential diagnosis), an evaluation of olfactory loss using Sniffin' Sticks Test® (SST)<sup>(19)</sup>, the  
111 completion of the French short version of *Questionnaire of Olfactory Disorders* (Short-QOD-  
112 NS)<sup>(20)</sup> and the completion of the French SF-36<sup>(21)</sup>. Patients were trained to a daily use of the  
113 OT protocol (detailed below) for 6 months. A second consultation (6 months ± 15 days) after  
114 OT allowed to assess a second time all the same elements except nasofibroscope. We finally  
115 retrieved OT compliance through a score calculated according to this formula: (((number of  
116 OT weeks done/24) – (number of OT sessions missed per week / 14))/ number of OT weeks  
117 done) \* 100.

118

119

## 120 **Objective olfactory dysfunction**

121 Olfactory function was assessed using Sniffin' Sticks test, a validated psychophysical  
122 test that included a phenyl-ethyl alcohol (PEA) odor Threshold detection (T), an odor  
123 Discrimination (D) and an odor Identification (I) test. The detailed procedure has already  
124 been detailed previously<sup>(22)</sup>. Results from the three tests were summed up to a composite  
125 score, the "TDI". As described by the last update of TDI normative values<sup>(19)</sup>, normosmia,  
126 hyposmia and anosmia was respectively defined by a  $TDI \geq 30.75$ ,  $30.5 \geq TDI \geq 16.25$ , and  
127  $TDI \leq 16$ . Concerning isolated T, D and I values, a normal or reduced olfactory function,  
128 related to gender and age, was respectively defined as  $\geq 10$ th percentile and  $< 10$ th percentile  
129 subdimension score based on<sup>(19)</sup>.

130

## 131 **Olfactory training**

132 OT was here based on Hummel protocol<sup>(17)</sup>, whose regenerative properties on  
133 olfactory neurons, olfactory cortex connectivity and olfactory scores are widely reported in  
134 the literature<sup>(15,18,23)</sup>. Therefore, the protocol was explained to patients. It involved 6-months  
135 olfactory training with daily odors exposure, twice a day (2 sessions), with 2 different  
136 random odors of the kit, the morning and the evening (four different odors per day). We  
137 decided to run the olfactive training for 6 months as it is described<sup>(24)</sup> as more effective than  
138 12 weeks firstly described protocol<sup>(17)</sup>, especially since odors are renewed every 3 months<sup>(15)</sup>.  
139 Patients were well-informed, once all odors used at least one time, to try to recognize by  
140 blindly sniffing them. To improve compliance and ludic aspects of the OT, we used other  
141 odors than the 4 common ones (Phenylethyl alcohol [Rose], Eucalyptol [Eucalyptus],  
142 Citronellal [Citronella], Eugenol [Clove])<sup>(17)</sup>. We used an olfaction training kit, produced

143 specially for this purpose by local industry, including 11 small pots of scented wax (10g),  
144 impregnated with 15% of dill, thyme, cinnamon, cloves, coriander leaf, vinegar, cumin,  
145 lavender, coffee, vanilla, or mint. We used different type of odors because there is no  
146 significant difference in olfaction improvement using simple or complex odors, or  
147 combination of both<sup>(25)</sup>.

148

#### 149 **Olfactory quality of life**

150 The olfactory QoL was assessed using the French validated Short-QOD-NS<sup>(20)</sup> self-  
151 questionnaire (2 min) which is based on negative statements from the Questionnaire of  
152 Olfactory Disorders (QOD), but shorter, allowing an increase of the response rate and  
153 reducing the patient's mental load when completing the questionnaire. These negative  
154 statements of QOD has been shown to be more correlated with the results of psychophysical  
155 olfactory tests (SST)<sup>(26)</sup>. The Short-QOD-NS<sup>(27)</sup> evaluate the 7 most relevant questions related  
156 to social aspects (n = 3), eating (n = 2), anxiety (n = 1) and annoyance (n = 1) following an  
157 olfactory loss. The score ranges from 0 to 21 (21 meaning there is no disorder).

158 The 36-item form health survey (SF-36) is one of the most widely used generic  
159 questionnaires, validated in French by Perneger et al.<sup>(28)</sup>, used here to evaluate general QoL.  
160 The SF-36 questionnaire consists on 36 self-administered questions (5min) divided in eight  
161 domains, covering both physical and mental health. The physical component summary  
162 covers 4 subdomains as initially described: *physical functioning*, *role physical functioning*,  
163 *bodily pain*, and *general health*. The mental component summary covers 4 other domains:  
164 *vitality*, *emotional functioning*, *social functioning*, and *mental health*. The sum of the score is  
165 calculated for each domain and scaled on 100. High scores indicate good QoL while low  
166 scores indicate low QoL.





## 168 **Statistical Analysis**

169 To explore the evolution of quantitative variables (e.g., TDI scores) before and after  
170 the OT, we employed Wilcoxon signed-rank tests, as most of the data did not follow a  
171 normal distribution (as confirmed by Shapiro-Wilks tests). To compare the evolution of  
172 binary variables (e.g, presence of parosmia, phantosmia), we employed McNemar test. To  
173 compare quantitative variables (such as TDI scores) between different groups of participants  
174 (e.g., participants with vs without parosmia) we employed Mann-Whitney tests. Non-  
175 parametric correlations (Spearman rho) were employed to investigate correlations between  
176 treatment compliance and improvement in TDI scores. All results were considered  
177 statistically significant for a bilateral alpha level of 0,05.

178 **RESULTS**

179

180 **Demographic and clinical features**

181 Forty-three patients were included in the study. The demographic and clinical initial  
182 features are reported in Table 1.

183 Patients were seen  $5,8 \pm 3,2$  months and  $11 \pm 3,7$  months after COVID-19 infection  
184 respectively at the first and the second (after OT) visit. Twenty-eight patients received a  
185 COVID-19 related treatment (of which 6 and 2 took respectively oral and nasal  
186 corticosteroids from 1 to 3 weeks). Among people who had a medical history of self-immune  
187 diseases, 2 had Crohn's disease and 1 had ankylosing spondylitis. Some had a medical history  
188 of neurological diseases, 2 had epilepsy under specific medications, 1 had stroke during  
189 childhood with no sequelae. Nasofibrosopies found no obstructive pathologies in the  
190 olfactory cleft.

191 On average, patients lost weight between the 2 visits before and after OT, going from  
192  $69,8 \pm 13,3$ kg to  $66,7 \pm 20,1$ kg, but the weight reduction was not statistically significant ( $Z = -$   
193  $0,88$ ,  $p = 378$ ). VAS Subjective olfactory recovery significantly increased from  $34,6 \pm 26,5\%$  to  
194  $57,9 \pm 31,1\%$  ( $Z = -4,71$ ,  $p < 0,001$ ). A slight, but not significant, decrease from 37 to 32 patients  
195 (74,4%) of chemosensorial complaints was reported after OT ( $p = 0,125$ ), with 30 (69,8%) and  
196 5 (11,6%) patients who still suffered from flavors and/or taste loss after the OT.

		mean	SD
197	<b>Age (years)</b>	41	13
198	<b>Months post-COVID-19</b>	5,8	3,2
199		n	%
200	<b>Total</b>	43	100
200	<b>Sex</b>		
201	Female	26	61
201	Male	17	39
202	<b>Medical history</b>		
202	Smokers	8	18,6
203	Type II diabetes	2	4,6
203	HTA	1	2,3
204	GERD	3	7
204	Neurological diseases	3	7
205	Self-immune diseases	3	7
205	<b>Chronic rhinosinusitis</b>		
206	• Allergic	16	37,2
206	• CRSnNP	5	11,6
207	• CRSwNP	0	0
207	Neurologic diseases	3	7
208	<b>COVID-19 Severity</b>		
209	Mild to moderate illness	40	93
209	Severe illness	3	7
210	<b>Chemo sensorial</b>		
211	<b>complain</b>	37	86
211	Flavors impairment	35	81,4
212	Taste impairment:	10	23,3

213 *Table 1 – Demographics and initial clinical patients features. HTA=hypertension; GERD=gastroesophageal reflux*  
 214 *disease; CRASnNP=chronic rhinosinusitis without nasal polyps; CRASwNP=chronic rhinosinusitis with nasal*  
 215 *polyps*

216

## 217 **Olfactory training results**

218 **TDI** - These was a significant improvement in the mean TDI score ( $Z=-4,71$ ,  $p<0,001$ ),  
219 which increased from 24,7 ( $\pm 8,9$ ) before the OT to 30,9 ( $\pm 9,8$ ) after the OT. A significant  
220 change in the number of participants categorized as anosmic, hyposmic and normosmic  
221 before and after the training was found ( $\text{Chi}^2= 25,7$ ,  $p<0,001$ ). Specifically, the number of  
222 anosmic participants decreased from 10 (23,3%) to 5 (11,6%); the number of hyposmic  
223 decreased from 22 (51,2%) to 11 (25,6%); and the number of normosmic participants  
224 increased from 11 (25,6%) to 27 (62,8%). These results are graphically reported in Figure 1.

225 The T and I scores significantly improved after the OT (from  $4,9\pm 3,9$  to  $8,7\pm 5,2$ ,  $Z=-$   
226  $4,67$ ,  $p<0,001$ ; and from  $9,4\pm 4,1$  to  $11,0\pm 3,4$ ,  $Z=-3,60$ ,  $p<0,001$ , respectively). No significant  
227 evolution of the D score was observed (from  $10,4\pm 3,0$  to  $11,2\pm 3,3$ ,  $Z=-1,60$ ,  $p=0,110$ ). The  
228 improvement in T was significantly bigger than the improvement in D ( $Z=-4,1$ ,  $p<0,001$ ) and I  
229 ( $Z= -2,7$ ,  $p=0,007$ ). T Improvement was significantly correlated with subjective recovery  
230 evaluation (VAS,  $p=0,039$ ). Concerning the evolution of the number of participants that  
231 reached the norms for T, D, and I (based on normative datas divided by sex and age), a  
232 significant increase in normalized value was only found for the T (McNemar test,  $p<0,001$ )  
233 but not for the D (McNemar test,  $p=0,774$ ) or the I (McNemar test,  $p=0,388$ ). Based on age  
234 and sex normatives values, the number of participants who had normal T, D and I before and  
235 after the OT are presented in Figure 2. No clinical, medical history, treatment or compliance  
236 predictive value was significantly correlated to better psychophysical tests results.


237

238

239


240

241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254



255 *Figure 1 – Evolution of individual TDI scores before and after OT. Colored parts cover anosmic (red), hyposmic*  
256 *(yellow) or normosmic (green) patients according to TDI normative values<sup>(19)</sup>. Oblique lines represent a patient*  
257 *anosmic (red), hyposmic (yellow) or normosmic (green) subject evolution according to post OT olfactory*  
258 *evaluation. Solid, dashed or pointed lines represent patients who respectively did not changed category,*  
259 *changed to the upper category, or changed from anosmic to normosmic category.*

260  
261



262

263 *Figure 2 - T, D & I normalization based on age and sex normative values. Number of patients who*  
264 *normalized T, D, and I values, before and after the OT, based on age and sex normative values.*

265

266 **Compliance** - Patients performed  $14,5 \pm 9$  weeks ( $\sim 3,5$  months) of OT on average, missing  
267  $0,8 \pm 1$  entire day per week, and  $3 \pm 3$  sessions per week. The average compliance ratio was  
268  $53 \pm 33\%$ , ranging from 4% to 110% (for people that did more than 24 weeks). There was no  
269 significant correlation between OT compliance and TDI evolution or subjective olfaction  
270 evaluation recovery – VAS, or improvements in quality of life (all  $p > 0,101$ ).

271

272 **Qualitative dysosmia** - The number of participants reporting the presence of parosmia  
273 increased significantly from 8 (18,6%) to 27 (62,8%) after the OT (McNemar test,  $p < 0,001$ ),  
274 with only 1 participant (2%) that fully recovered after the OT, and 20 participants (46,5%)  
275 that developed parosmia after the OT. At the end of the OT, participants presenting  
276 parosmia showed lower identification scores ( $U = 122$ ,  $p = 0,018$ ). Patients with parosmia were  
277 significantly less likely to lose weight ( $Z = -2,4$ ;  $p = 0,013$ ). No significant difference in the  
278 number of participants reporting phantosmia was found (9 participants – 20,9% - before the

279 OT, and 12 - 27.9% - after the OT,  $p=0,581$ ; 8 subjects – 18,6% - developed phantosmia after  
280 the OT, and 5 – 11,6% - recovered after the OT). No predictive factor was significantly  
281 associated with qualitative dysosmia evolution.

282

283 **Quality of life** - The results of the SF36 and the Short-QOD-NS questionnaires are reported in  
284 Table 2. Concerning the SF36, significant improvements after the OT were obtained in the  
285 subdomains assessing physical functioning ( $p=0,009$ ), social functioning ( $p=0,013$ ),  
286 emotional role ( $p=0,049$ ), vitality ( $p=0,023$ ), and general health perception ( $p=0,045$ ). For the  
287 Short-QOD-NS, significant improvements after the OT were observed for the total score  
288 ( $p<0,001$ ) and all the subdomains, namely the social ( $p=0.001$ ), the food ( $p=0,036$ ), the  
289 anxiety ( $p=0,020$ ), and the annoyance ( $p=0,020$ ) subdomains. Short-QOD-NS improvement  
290 was significantly correlated to a TDI improvement after OT ( $p=0,008$ ).

Quality of life Score	BEFORE OT		AFTER OT		<i>p</i>
	Mean	ET	Mean	ET	
<b>Short-QOD-NS</b>					
<i>Total score</i>	10,44	5,97	13,65	6,49	<0,001***
<i>Social subdomain</i>	4,58	2,7	5,88	2,86	0,001**
<i>Food subdomain</i>	2,98	2,22	3,72	2,42	0,036*
<i>Anxiety subdomain</i>	1,91	1,02	2,44	1,12	0,020*
<i>Annoyance subdomain</i>	0,98	1,03	1,60	1,20	0,020*
<b>SF36</b>					
<i>Physical functioning</i>	79,53	25,42	85,81	23,20	0,009**
<i>Social functioning</i>	66,28	28,68	74,13	26,78	0,013*
<i>Physical role</i>	66,28	40,42	71,51	38,80	0,407
<i>Emotional role</i>	55,81	41,61	64,34	42,04	0,049*
<i>General mental health</i>	62,05	21,60	61,11	21,33	0,844
<i>Vitality</i>	44,54	24,07	51,86	21,63	0,023*
<i>Bodily pain</i>	66,61	31,64	69,63	33,51	0,337
<i>General health perception</i>	63,63	26,09	69,56	23,22	0,045*

291

292 *Table 2 – Olfactory specific (Short-QOD-NS) and general (SF-36) quality of life comparative results before and*

293 *after OT. p represents the p-value at the Wilcoxon signed-rank test. \*p<0,05; \*\*p<0,01; \*\*\*p<0,001*

294



295 **DISCUSSION**

296

297 Persistent post-COVID olfactory loss is becoming a social issue as millions of people  
298 worldwide are affected. OT is, for the moment, the only therapeutic hope for post-COVID-19  
299 olfactory impaired patients who are still complaining of it many months after contamination,  
300 despite spontaneous olfactory recovery occurring in 40<sup>(2)</sup> to 70%<sup>(4)</sup> of cases from 6 to 12  
301 months. For now, only a few studies reported the OT efficiency in post-COVID-19 PPVOD.

302 This study reports a significant olfactory recovery after ~3,5 months of OT in PPVOD  
303 related to COVID-19. The SST MCID increased by more than 6 points<sup>(17)</sup> in average  
304 suggesting, in this situation, the OT efficiency as already knew for non-COVID-19 related  
305 PPVOD<sup>(15,18,24,25)</sup>. Interestingly, we observed more than a doubling normosmic patients' ratio  
306 after OT, going from 11 (25,6%) to 27 (62,6%).

307 Specific to COVID-19, OT results were only reported with complete SST results in Le  
308 bon et al.<sup>(29)</sup> study that compared 10 weeks of OT with (n=9) or without (n=18) a 10 days oral  
309 corticosteroids course. In this study, there was no significant olfactory recovery in OT alone  
310 group but report 2 nonhomogeneous groups and a poor compliance for 31% of patients.  
311 Olfactory subdimensions (T, D and I) specific recoveries were not reported by authors<sup>(29)</sup>. In  
312 COVID-19 PPVOD, OT alone was reported as significantly improving olfaction recovery only  
313 in other steroids efficiency evaluations studies but never again with a complete SST  
314 evaluation<sup>(30,31)</sup>. However, it is recommended<sup>(15)</sup> to integrate T, D and I studies in olfactory  
315 evaluation. Indeed, OT effect on T, D and I in case of PPVOD is still unclear. Hummel firstly  
316 described a clear T increasing effect<sup>(17)</sup> of OT. So, according to our results, Oleszkiewicz et  
317 al.<sup>(25)</sup> reported a significant increasing effect on T and I in OT efficiency on post-infectious  
318 (n=57) and idiopathic (n=51) olfactory long lasting dysfunctions. T-recovery could be

319 explained by a peripheral regenerative<sup>(32)</sup> effect of OT with a regrowth of olfactory  
320 neurons<sup>(33)</sup> ; and I-recovery (with D-recovery) by a more central processing allowing an  
321 olfaction dedicated area connectivity reorganization<sup>(23,25)</sup>. More recently, Sorokowska et  
322 al.<sup>(24)</sup> reported in a meta-analysis (n>879) a large and significant post-OT increase both on D  
323 and I. However, they<sup>(24)</sup> also mentioned a small to moderate effect on T, which is in  
324 contradiction with our results despite that we used the same PEA threshold in both visits.  
325 According to these studies<sup>(17,24,25)</sup>, in a PPVOD situation, we report an expected significant T-  
326 recovery compared to an insufficient I and D-recovery, the two last being usually correlated  
327 to higher olfactory functions.

328 As potential neurological outcomes of COVID-19 PPVOD are getting more and more  
329 discussed in literature<sup>(34,35)</sup>, it could be an explanation for this lack of significant I-  
330 normalization and D-improvement. Moreover, the D is the only subdimension which did not  
331 significantly improved while it's well documented that the olfactory-hippocampal network is  
332 actively involved during a discrimination learning, and so OT<sup>(36)</sup>. Discrimination and  
333 identification tasks are closely related to cognition and specifically to executive functions,  
334 semantic task and episodic memory<sup>(37)</sup>. These cognitive functions might be affected by  
335 hypometabolism and dysfunctioning of many parts of secondary olfactory cortex areas, or  
336 areas connected to them, reported in 18FDG PET study<sup>(38)</sup> on COVID-19 PPVOD such as :  
337 bilateral orbito-frontal cortex, cingulate gyrus, thalamus, hippocampic or parahippocampic  
338 gyri. Theses cognitives and semantic isolated impaired areas could be part of a more global  
339 connectivity structure impairment suggested in a tractography study which is the inferior  
340 longitudinal fasciculus<sup>(35)</sup>. Moreover, MRI morphological (and functional) modifications of  
341 many of these cortical areas, especially gray matter volume of cingulate gyrus and  
342 hippocampus<sup>(39)</sup>, are reported to be correlated to COVID-19 persistent (≥3 months) smell

343 loss and could be the mark of a long lasting damage of dedicated olfactory areas. Currently,  
344 there is still some doubt regarding the etiology of central abnormalities observed as they are  
345 not proven to be the cause or the consequences of persistent olfactory loss, but the link  
346 between D and I impairment and impaired olfactory brain areas is becoming more and more  
347 obvious. These central involvement in post COVID-19 persistent olfactory loss may suggest a  
348 therapeutic approach consisting in the use of cognition and semantic training that could be  
349 mediated by speech therapist. It has to be evaluated in the future.

350 In our study, parosmias were multiplied by 3 after OT. Parosmia physiology is  
351 complex and poorly understood. It seems to be an olfactory epithelium regeneration side  
352 effect spontaneously emerging in 18%<sup>(8)</sup> to 43%<sup>(3,7)</sup> of COVID-19 PPVOD patients. Peripheral  
353 origin is supported by an abnormal neuronal regrowth, including bad proximity neurons  
354 contacts, in a hypotrophic olfactory bulbs environment<sup>(40)</sup>. Parosmias annoyance is not  
355 systematic ally correlated with olfactory function justifying it occurs sometimes after a total  
356 olfactory recovery in 2[here] to 20%<sup>(3)</sup>. Central origin is supported by gray matter  
357 alterations<sup>(41)</sup> and olfactory cortex hypometabolism<sup>(42)</sup>. Thus, the increasing parosmic  
358 patient's ratio could be linked to peripheral regeneration induced by OT, as suggested by the  
359 significant T increase. In contrast, the persistence of this symptom could be correlated to a  
360 lack of central processing suggested by the lack of I-recovery. Widely, the fact that D and I  
361 did not normalize could support a central involvement explanation for persistent post-  
362 COVID-19 olfactory loss.

363 Moreover, we found that parosmic patients did not lose weight, unlike non parosmic  
364 patients. Olfaction disorders is a well-known state correlated with abnormal human control  
365 of food intake portion size and decreased reward system signals and so satiety<sup>(43)</sup>. This study  
366 supports this effect as olfactory recovery seems to be associated with a slight but not

367 significant loose of weight acquired during the anosmic phase. However, when parosmias  
368 occurred, this could prevent this weight loose and increase a potential metabolic risk factor  
369 associated to salt and sugar intake increased in near 30% of COVID-19 patients, especially in  
370 case of anosmia<sup>(44)</sup>.

371 Smell loss cause a well-known significant QoL worsening<sup>(15,45)</sup>.The benefit of such a  
372 OT in COVID 19 PPVOD in still unknown but we previously reported an alteration of Short-  
373 QOD-NS<sup>(8)</sup>. In this study, we reported that OT not only induced significant improvement of  
374 Short-QOD-NS, but also general QoL through SF-36 results. All Short-QOD-NS sub-scores  
375 were significantly improved but mainly one related to social relationships. After a long  
376 olfactory deprivation time, patients get used to it and develop strategies to cope with  
377 parosmias such as avoiding food tasting or not smoke smelling. These behaviors generate  
378 anxiety, and patients suffer from social network reduction. Moreover, loneliness contributes  
379 to the 30% increase of depression and suicide in this specific population<sup>(46)</sup>. The *emotional*  
380 *role* and *vitality* SF-36 sub-domain improvements (table 2) are consistent with the fact that  
381 olfaction is more than just a food sense, but also a channel for social, sexual, and emotional  
382 communication. Healing from an olfactory loss seems to improve mental general state of  
383 patients. Smeets et al.<sup>(45)</sup> previously reported that all SF-36 subdimensions which improved  
384 in our study, except general mental health, were significantly impaired in case of severe  
385 dysosmia underlining the specific effect of OT on dysosmia related general QoL.

386 This study had however several limitations. We did not use a control group as it's  
387 often the case in OT study because it's ethically difficult not to treat a patient, and  
388 technically impossible or quite difficult to use placebo odors. Concerning TDI results, we can  
389 wonder if spontaneous recovery could have produced the same results. It's hard to answer  
390 to that question formally as, with similar complete (T,D,I) SST evaluations, there are only a

391 few studies reporting spontaneous post-COVID-19 olfactory recovery<sup>(47,48)</sup>, and even less  
392 reporting it after OT<sup>(29)</sup>. Iannuzzi et al.<sup>(49)</sup> found a significant T progression evaluated after 2  
393 months of spontaneous olfactory recovery, which may correspond to early olfactory neurons  
394 and sustentacular regeneration occurring around 2 to 4 weeks in such inflammatory  
395 environment<sup>(50)</sup>. Compared to D and I, we previously reported<sup>(8)</sup> that T was the most  
396 decreased olfaction subdimension measured in a cohort of patients with near 6 months  
397 post-COVID-19 PPVOD, confirming what many authors found in similar patients after 4<sup>(48)</sup> or  
398 6<sup>(47)</sup> months of spontaneous recovery with a tiny or non-significant increasing of T. There is,  
399 to date, no potential explanation that could validate a spontaneous T increasing after 6  
400 months of persistent post-COVID-19 olfactory loss. Spontaneous recovery occurred mainly in  
401 the first month and does not change afterward. Another limit is the absence of  
402 psychophysical taste evaluation even if, after 6 months, almost all patients no longer  
403 complained about it. Last main limit is the small sample size which can reduced the study  
404 strength. Therefore, our SST subdimensions OT results singularity must be confirmed with  
405 larger cohorts of patients.

406 **CONCLUSION**

407           In COVID-19 PPVOD, OT seems to significantly improve olfaction recovery, more than  
408 doubling normosmic patient' ratio. Olfaction subdimensions and qualitative dysosmias  
409 studies underline the main regenerative peripheral effect of OT as olfaction threshold  
410 significantly improved. Despite of olfaction, specific, and general patients' quality of life  
411 improvement, central involvement of persistent olfactory loss is becoming more and more  
412 significant and must be focused on future studies to improve olfactory quantitative and  
413 especially qualitative recovery.

414 **ACKNOWLEDGEMENTS**

415 Authors want to thank PAYAN BERTRAND perfumery society (28 Av. Jean XXIII, 06130 Grasse,  
416 France) who graciously manufactured olfaction training kits given to each patient in this  
417 study.

418

419 **AUTHORSHIP CONTRIBUTION**

420 CV, MP, EC, LED, AG contributed to study design, data collection, interpretation of results,  
421 drafting and critical evaluation of the final manuscript. AP, GD, DC, ED, KR, FA, CS, NG, PR  
422 and LC contributed to study design, interpretation of results, drafting and critical evaluation  
423 of the final manuscript. VM contributed to biostatistics, interpretation of results and critical  
424 evaluation of the final manuscript.

425

426 **CONFLICT OF INTEREST**

427 None declared

428

429 **FUNDING**

430 None declared

431

## 432 REFERENCES

- 433 1. Riestra-Ayora J, Yanes-Diaz J, Esteban-Sanchez J, et al. Long-term follow-up of  
434 olfactory and gustatory dysfunction in COVID-19: 6 months case-control study of  
435 health workers. *Eur Arch Oto-Rhino-Laryngology*. 2021;278(12):4831-7.
- 436 2. Lucidi D, Molinari G, Silvestri M, et al. Patient-reported olfactory recovery after  
437 SARS-CoV-2 infection: A 6-month follow-up study. *Int Forum Allergy Rhinol*.  
438 2021;11(8):1249-52.
- 439 3. Hopkins C, Surda P, Vaira LA, et al. Six month follow-up of self-reported loss of smell  
440 during the COVID-19 pandemic. *Rhinol J*. 2020;(11):0-0.
- 441 4. Boscolo-Rizzo P, Guida F, Polesel J, et al. Self-reported smell and taste recovery in  
442 coronavirus disease 2019 patients: a one-year prospective study. *Eur Arch Oto-Rhino-*  
443 *Laryngology*. 2022;279(1):515-20.
- 444 5. Lechien JR, Chiesa-Estomba CM, Beckers E, et al. Prevalence and 6-month recovery of  
445 olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. *J Intern Med*.  
446 2021;290(2):451-61.
- 447 6. Petrocelli M, Cutrupi S, Salzano G, et al. Six-month smell and taste recovery rates in  
448 coronavirus disease 2019 patients: A prospective psychophysical study. *J Laryngol*  
449 *Otol*. 2021;135(5):436-41.
- 450 7. Arnaud T, Evelina T, Mats JO, et al. High prevalence of olfactory disorders 18 months  
451 after contracting COVID-19. *medRxiv*. 2022;
- 452 8. Vandersteen C, Payne M, Dumas L-E, et al. Persistent olfactory complaints after  
453 COVID-19: a new interpretation of the psychophysical olfactory scores. *Rhinol Online*.  
454 2021;4(14):66-72.
- 455 9. Aschenbrenner K, Hummel C, Teszmer K, et al. The Influence of Olfactory Loss on



- 456 Dietary Behaviors. *Laryngoscope*. 2008;118(1):135–44.
- 457 10. Valsamidis K, Printza A, Constantinidis J, Triaridis S. The Impact of Olfactory  
458 Dysfunction on the Psychological Status and Quality of Life of Patients with Nasal  
459 Obstruction and Septal Deviation. *Int Arch Otorhinolaryngol*. 2020;24(02):e237–46.
- 460 11. Hur K, Choi JS, Zheng M, Shen J, Wrobel B. Association of alterations in smell and taste  
461 with depression in older adults. *Laryngoscope Investig Otolaryngol*. 2018;3(2):94–9.
- 462 12. Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life-an updated review.  
463 *Chem Senses*. 2014;39(3):185–94.
- 464 13. Nordin S. Sensory perception of food and ageing. In: *Food for the Ageing Population*.  
465 Elsevier; 2009. p. 73–94.
- 466 14. Pence TS, Reiter ER, DiNardo LJ, Costanzo RM. Risk Factors for Hazardous Events in  
467 Olfactory-Impaired Patients. *JAMA Otolaryngol Neck Surg*. 2014;140(10):951.
- 468 15. Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction.  
469 *Rhinol J*. 2017;54(26):1–30.
- 470 16. Webster KE, O’Byrne L, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for  
471 the prevention of persistent post-COVID-19 olfactory dysfunction. *Cochrane Database*  
472 *Syst Rev*. 2021;2021(8):CD013877.
- 473 17. Hummel T, Rissom K, Reden J, Hähner A, Weidenbecher M, Hüttenbrink K-B. Effects of  
474 olfactory training in patients with olfactory loss. *Laryngoscope*. 2009;119(3):496–9.
- 475 18. Kattar N, Do TM, Unis GD, Migneron MR, Thomas AJ, McCoul ED. Olfactory Training  
476 for Postviral Olfactory Dysfunction: Systematic Review and Meta-analysis. *Otolaryngol*  
477 *Neck Surg*. 2021;164(2):244–54.
- 478 19. Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T. Updated Sniffin’ Sticks  
479 normative data based on an extended sample of 9139 subjects. *Eur Arch Oto-Rhino-*

- 480 Laryngology. 2019;276(3):719–28.
- 481 20. Leclercq C, Chiesa-Estomba CM, Horoi M, et al. Validity and Reliability of the French  
482 Short Version of the Questionnaire of Olfactory Disorders-Negative Statements  
483 (sQOD-NS). *Ear, Nose Throat J.* 2021;014556132110320.
- 484 21. Leplège A, Ecosse E, Coste J, Pouchot J, Perneger T. Le questionnaire MOS SF-36:  
485 manuel de l'utilisateur et guide d'interprétation des scores. Paris: Editions ESTEM;  
486 2001. 156 p.
- 487 22. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin' Sticks': Olfactory  
488 Performance Assessed by the Combined Testing of Odour Identification, Odor  
489 Discrimination and Olfactory Threshold. *Chem Senses.* 1997;22(1):39–52.
- 490 23. Kollndorfer K, Fischmeister FPS, Kowalczyk K, et al. Olfactory training induces changes  
491 in regional functional connectivity in patients with long-term smell loss. *NeuroImage*  
492 *Clin.* 2015;9:401–10.
- 493 24. Sorokowska A, Drechsler E, Karwowski M, Hummel T. Effects of olfactory training: a  
494 meta-analysis. *Rhinol J.* 2017;55(1):17–26.
- 495 25. Oleszkiewicz A, Hanf S, Whitcroft KL, Haehner A, Hummel T. Examination of olfactory  
496 training effectiveness in relation to its complexity and the cause of olfactory loss.  
497 *Laryngoscope.* 2018;128(7):1518–22.
- 498 26. Simopoulos E, Katotomichelakis M, Gouveris H, Tripsianis G, Livaditis M, Danielides V.  
499 Olfaction-associated quality of life in chronic rhinosinusitis: Adaptation and validation  
500 of an olfaction-specific questionnaire. *Laryngoscope.* 2012;122(7):1450–4.
- 501 27. Mattos JL, Edwards C, Schlosser RJ, et al. A brief version of the questionnaire of  
502 olfactory disorders in patients with chronic rhinosinusitis. *Int Forum Allergy Rhinol.*  
503 2019;9(10):1144–50.

- 504 28. Perneger T V., Leplège A, Etter J-F, Rougemont A. Validation of a French-language  
505 version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults.  
506 *J Clin Epidemiol.* 1995;48(8):1051–60.
- 507 29. Le Bon S-D, Konopnicki D, Pisarski N, Prunier L, Lechien JR, Horoi M. Efficacy and  
508 safety of oral corticosteroids and olfactory training in the management of COVID-19-  
509 related loss of smell. *Eur Arch Oto-Rhino-Laryngology.* 2021;278(8):3113–7.
- 510 30. Saussez S, Vaira LA, Chiesa-Estomba CM, et al. Short-term efficacy and safety of oral  
511 and nasal corticosteroids in covid-19 patients with olfactory dysfunction: A European  
512 multicenter study. *Pathogens.* 2021;10(6):1–14.
- 513 31. Abdelalim AA, Mohamady AA, Elsayed RA, Elawady MA, Ghallab AF. Corticosteroid  
514 nasal spray for recovery of smell sensation in COVID-19 patients: A randomized  
515 controlled trial. *Am J Otolaryngol.* 2021;42(2):102884.
- 516 32. Ojha P, Dixit A. Olfactory training for olfactory dysfunction in COVID-19: A promising  
517 mitigation amidst looming neurocognitive sequelae of the pandemic. *Clin Exp*  
518 *Pharmacol Physiol.* 2022;(September 2021):1–12.
- 519 33. Hummel T, Stupka G, Haehner A, Poletti SC. Olfactory training changes  
520 electrophysiological responses at the level of the olfactory epithelium. *Rhinology.*  
521 2018;56(4):330–5.
- 522 34. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion  
523 as a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci.*  
524 2021;24(2):168–75.
- 525 35. Donegani MI, Miceli A, Pardini M, et al. Brain Metabolic Correlates of Persistent  
526 Olfactory Dysfunction after SARS-Cov2 Infection. *Biomedicines.* 2021;9(3):287.
- 527 36. Martin C, Beshel J, Kay LM. An Olfacto-Hippocampal Network Is Dynamically Involved

- 528 in Odor-Discrimination Learning. *J Neurophysiol.* 2007;98(4):2196–205.
- 529 37. Hedner M, Larsson M, Arnold N, Zucco GM, Hummel T. Cognitive factors in odor  
530 detection, odor discrimination, and odor identification tasks. *J Clin Exp Neuropsychol.*  
531 2010;32(10):1062–7.
- 532 38. Karimi-Galougahi M, Yousefi-Koma A, Bakhshayeshkaram M, Raad N, Haseli S. 18FDG  
533 PET/CT Scan Reveals Hypoactive Orbitofrontal Cortex in Anosmia of COVID-19. *Acad*  
534 *Radiol.* 2020;27(7):1042–3.
- 535 39. Lu Y, Li X, Geng D, et al. Cerebral Micro-Structural Changes in COVID-19 Patients – An  
536 MRI-based 3-month Follow-up Study. *EClinicalMedicine.* 2020;25(2):100484.
- 537 40. Parker JK, Kelly CE, Gane SB. Molecular Mechanism of Parosmia. medRxiv.  
538 2021;2021.02.05.21251085.
- 539 41. Bitter T, Siegert F, Gudziol H, et al. Gray matter alterations in parosmia. *Neuroscience.*  
540 2011;177:177–82.
- 541 42. Iannilli E, Leopold DA, Hornung DE, Hummel T. Advances in Understanding Parosmia:  
542 An fMRI Study. *ORL.* 2019;81(4):185–92.
- 543 43. Meunier N, Briand L, Jacquin-Piques A, Brondel L, Pénicaud L. COVID 19-Induced Smell  
544 and Taste Impairments: Putative Impact on Physiology. *Front Physiol.*  
545 2021;11(January):1–12.
- 546 44. Vandersteen C, Payne M, Dumas LÉ, et al. What about using sniffin’ sticks 12 items  
547 test to screen post-COVID-19 olfactory disorders? *Eur Arch Oto-Rhino-Laryngology.*  
548 2021;
- 549 45. Smeets MAM, Veldhuizen MG, Galle S, et al. Sense of Smell Disorder and Health-  
550 Related Quality of Life. *Rehabil Psychol.* 2009;54(4):404–12.
- 551 46. Yom-Tov E, Lekkas D, Jacobson NC. Association of COVID19-induced anosmia and

- 552 ageusia with depression and suicidal ideation. *J Affect Disord Reports*.  
553 2021;5(January):100156.
- 554 47. Bordin A, Mucignat-Caretta C, Gaudio P, et al. Comparison of self-reported  
555 symptoms and psychophysical tests in coronavirus disease 2019 (COVID-19) subjects  
556 experiencing long-term olfactory dysfunction: a 6-month follow-up study. *Int Forum*  
557 *Allergy Rhinol*. 2021;11(11):1592–5.
- 558 48. Niklassen AS, Draf J, Huart C, et al. COVID-19: Recovery from Chemosensory  
559 Dysfunction. A Multicentre study on Smell and Taste. *Laryngoscope*.  
560 2021;131(5):1095–100.
- 561 49. Iannuzzi L, Salzo AE, Angarano G, et al. Gaining Back What Is Lost: Recovering the  
562 Sense of Smell in Mild to Moderate Patients After COVID-19. *Chem Senses*.  
563 2020;45(9):875–81.
- 564 50. de Melo GD, Lazarini F, Levallois S, et al. COVID-19–related anosmia is associated with  
565 viral persistence and inflammation in human olfactory epithelium and brain infection  
566 in hamsters. *Sci Transl Med*. 2021;13(596).  
567



